WARMTH patients only received a median of three cycles because Lu-PSMA was no longer effective after that point.
The median of 5 cycles in LuPIN is a big plus for NOX66: the combination of NOX66 and Lu-PSMA worked for a longer time, which is good for patients; and Novartis would be able to charge their fees for additional cycles, which would be good for Novartis.
Ann: New Independent Trial Data Supports Potential of Veyonda, page-18
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.5¢ | 10.5¢ | $2.964K | 26.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 53298 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 33616 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| NOX (ASX) Chart |